Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03827876 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03827876 · ClinicalTrials.gov record · last posted 2019-02-04

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

Name: Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis — clinical trial record (NCT03827876)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorPsoriasis Treatment Center of Central New Jersey

Started2019-01-16

View on ClinicalTrials.gov ↗

Record status

This record was last updated February 4, 2019 (before its estimated September 15, 2019 completion). Its status may not reflect the trial's current state.

from the ClinicalTrials.gov record

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

Amendment record 1 amendment on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended once since 2019-01-31. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-03-14

Status change Recruiting→Completedv1

Trial Details

NCT Number	NCT03827876
Lead Sponsor	Psoriasis Treatment Center of Central New Jersey Collaborators: LEO Pharma
Conditions	Psoriasis
Enrollment	30 participants
Start Date	2019-01-16
Primary Completion	2019-09-15 (estimated)
Study Completion	2019-12-15 (estimated)
Updated on ClinicalTrials.gov	2019-02-04